DIA Biosimilars 2013

PharMerica

PharMerica introduces $25M share purchase program

Tuesday, July 3, 2012 09:22 AM

The board of directors of PharMerica, a national provider of institutional pharmacy and hospital pharmacy management services, has authorized an increase in its existing share purchase program that will allow the company to purchase up to $25 million of its common stock in the open market through unsolicited or solicited privately negotiated transactions, or in such other appropriate manner, and will be funded from available cash.

More... »

Cenduit: Now with Patient Reminders

PharMerica adopts poison pill to prevent takeover

Friday, August 26, 2011 01:25 PM

U.S. pharmacy services provider PharMerica adopted a poison pill to prevent hostile takeovers, two days after Omnicare went public with its bid to acquire the company for $441 million, according to Reuters.

More... »

CRF Health – eCOA Forum

Omnicare offers $457 million to buy PharMercia

Wednesday, August 24, 2011 01:12 PM

Omnicare went public with a $457 million offer for pharmacy management services company PharMerica, sending shares of both companies surging.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs